InvestSMART

Innate Immunotherapeutics Limited (ASX: IIL) - Announcements

Current share price for IIL : $0.360 0.02 (5.88%)+

ASX company news and announcements for Innate Immunotherapeutics Limited (IIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Innate Immunotherapeutics Limited (IIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Innate Immunotherapeutics Limited (IIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Innate Immunotherapeutics Limited (IIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Appendix 3B - Final Allotment of Placement 2 Shares 26 Sep 2016 12:38AM $0.500 $0.360 fallen by 28%
- Change in substantial holding from AEF 15 Sep 2016 9:42AM $0.520 $0.360 fallen by 30.77%
- Change in substantial holding - Chris Collins 15 Sep 2016 8:28AM $0.520 $0.360 fallen by 30.77%
- Revised App 3Y - Elizabeth Hopkins 14 Sep 2016 8:55AM $0.530 $0.360 fallen by 32.08%
- Change of Director's Interest Notice - Dr. Robert Peach 12 Sep 2016 7:16PM $0.540 $0.360 fallen by 33.33%
- Change of Director's Interest Notice - Elizabeth Hopkins 12 Sep 2016 7:14PM $0.540 $0.360 fallen by 33.33%
- Change of Director's Interest Notice - Andrew Sneddon 12 Sep 2016 7:13PM $0.540 $0.360 fallen by 33.33%
- Change of Director's Interest Notice - Chris Collins 12 Sep 2016 7:13PM $0.540 $0.360 fallen by 33.33%
- Change of Director's Interest Notice - Simon Wilkinson 12 Sep 2016 7:12PM $0.540 $0.360 fallen by 33.33%
- Change of Director's Interest Notice - Michael Quinn 12 Sep 2016 7:12PM $0.540 $0.360 fallen by 33.33%
- Section 708A Cleansing Notice Placements 1 and 2 12 Sep 2016 4:43PM $0.540 $0.360 fallen by 33.33%
- Appendix 3B Placements 1 and 2 and Options post AGM. 12 Sep 2016 4:34PM $0.540 $0.360 fallen by 33.33%
- Results of Annual General Meeting 31 Aug 2016 4:40PM $0.405 $0.360 fallen by 11.11%
- Clinical Trials Update - 2016 Bioshares Biotech Summit 2 Aug 2016 8:54AM $0.400 $0.360 fallen by 10%
- Appendix 4G - Key to Corporate Governance Disclosures 29 Jul 2016 3:49PM $0.400 $0.360 fallen by 10%
- 2016 Corporate Governance Statement 29 Jul 2016 3:48PM $0.400 $0.360 fallen by 10%
- Annual Report to shareholders - YE 31 March 2016 29 Jul 2016 3:47PM $0.400 $0.360 fallen by 10%
- Notice of Annual General Meeting/Proxy Form 29 Jul 2016 3:45PM $0.400 $0.360 fallen by 10%
- Appendix 4C - quarterly - June 16 Qtr 29 Jul 2016 10:38AM $0.420 $0.360 fallen by 14.29%
- Change in substantial holding from AEF 20 Jul 2016 12:11PM $0.380 $0.360 fallen by 5.26%
- Final Stage of Capital Raising Programme Completed 20 Jul 2016 9:21AM $0.385 $0.360 fallen by 6.49%
- Change Director's Interest - Andrew Sneddon - Rights Issue 14 Jul 2016 4:24PM $0.380 $0.360 fallen by 5.26%
- Change of Director's Interest - Michael Quinn - Rights Issue 14 Jul 2016 4:00PM $0.380 $0.360 fallen by 5.26%
- Change Director's Interest - Simon Wilkinson - Rights Issue 13 Jul 2016 5:08PM $0.375 $0.360 fallen by 4%
- Rights Issue Strongly Supported 7 Jul 2016 5:32PM $0.440 $0.360 fallen by 18.18%

101 - 125 of 191 results

Page 5 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.